Kintor Pharmaceutical, based in China has just finished enrolling patients for its phase II trial of a new treatment for Female Androgenetic alopecia (AGA).
The treatment, called pyrilutamide (KX-826), is an androgen receptor antagonist applied topically to treat both AGA and acne vulgaris.
The enrolment began around four months ago and resulted in a total of 160 patients. Going forward, the safety and efficacy will be measured through a randomized, double-blind, placebo-controlled clinical trial. The primary endpoint is variation in non-vellus target area hair counts (vellus hair is commonly called “peach fuzz” and is the fine hair that covers most of the body, so non-vellus hair counts look at the hair loss that occurs in other areas such as on the scalp and in the eyebrows.)
There are 15 hospitals taking part in the trial, all led by Pekin University People’s Hospital.
Last year, a similar trial on male participants using KX-826 met the primary endpoint with a favorable safety profile. Another phase II trial of male participants is taking place in the US, where the first patient has just been dosed, alongside the current female trial in China.
Want to Learn More?
In addition to keeping you up to date on all things clinical trials, we also act as a digital CRO with a specific focus on patient recruitment and retention. We believe that patient recruitment and study startup (especially study design and study material) are heavily intertwined. After all, study design can make or break clinical trials, and the patient perspective should be considered when designing studies to ensure that patient targets are met not only on time but also on budget.
For Citruslabs, patient recruitment starts with study design and ends with trial completion. We recruit patients through our network of health apps, which enables you to connect with thousands of patients in real-time. The best part: these patients are already educated and prepared for the clinical trial process.
Comments